<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">09-PLPA-RA-1244R3</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1000742</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Microbiology</subject><subject>Oncology</subject><subject>Virology</subject></subj-group></article-categories><title-group><article-title>Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress</article-title><alt-title alt-title-type="running-head">Upregulation of xCT by KSHV-Encoded MicroRNAs</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Qin</surname><given-names>Zhiqiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Freitas</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sullivan</surname><given-names>Roger</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohan</surname><given-names>Sarumathi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bacelieri</surname><given-names>Rocky</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Branch</surname><given-names>Drake</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Romano</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kearney</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Oates</surname><given-names>Jim</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Plaisance</surname><given-names>Karlie</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Renne</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kaleeba</surname><given-names>Johnan</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Parsons</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Craniofacial Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Department of Dermatology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Department of Pathology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Medical Service, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States of America</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Department of Molecular Genetics and Microbiology, Shands Cancer Center, University of Florida, Gainesville, Florida, United States of America</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>Departments of Microbiology and Immunology and Molecular/Cell Biology, Uniformed Services University of the Health Sciences, F. Edward Herbert School of Medicine, Bethesda, Maryland, United States of America</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Mesri</surname><given-names>Enrique A.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">University of Miami, United States of America</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">jkaleeba@usuhs.mil</email> (JK); <email xlink:type="simple">parsonch@musc.edu</email> (CP)</corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: ZQ RR JK CP. Performed the experiments: ZQ EF RS SM MR PK KP. Analyzed the data: ZQ RB DB CP. Contributed reagents/materials/analysis tools: JO JK. Wrote the paper: ZQ RR CP. Contributed to paper editing: JK.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>1</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2010</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>e1000742</elocation-id><history>
<date date-type="received"><day>23</day><month>7</month><year>2009</year></date>
<date date-type="accepted"><day>29</day><month>12</month><year>2009</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</license-p></license></permissions><abstract>
<p>Upregulation of xCT, the inducible subunit of a membrane-bound amino acid transporter, replenishes intracellular glutathione stores to maintain cell viability in an environment of oxidative stress. xCT also serves as a fusion-entry receptor for the Kaposi's sarcoma-associated herpesvirus (KSHV), the causative agent of Kaposi's sarcoma (KS). Ongoing KSHV replication and infection of new cell targets is important for KS progression, but whether xCT regulation within the tumor microenvironment plays a role in KS pathogenesis has not been determined. Using gene transfer and whole virus infection experiments, we found that KSHV-encoded microRNAs (KSHV miRNAs) upregulate xCT expression by macrophages and endothelial cells, largely through miR-K12-11 suppression of BACH-1—a negative regulator of transcription recognizing antioxidant response elements within gene promoters. Correlative functional studies reveal that upregulation of xCT by KSHV miRNAs increases cell permissiveness for KSHV infection and protects infected cells from death induced by reactive nitrogen species (RNS). Interestingly, KSHV miRNAs simultaneously upregulate macrophage secretion of RNS, and biochemical inhibition of RNS secretion by macrophages significantly reduces their permissiveness for KSHV infection. The clinical relevance of these findings is supported by our demonstration of increased xCT expression within more advanced human KS tumors containing a larger number of KSHV-infected cells. Collectively, these data support a role for KSHV itself in promoting <italic>de novo</italic> KSHV infection and the survival of KSHV-infected, RNS-secreting cells in the tumor microenvironment through the induction of xCT.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>Herpesviruses are the most common etiologic agents of cancer in patients with suppressed immune function, and the Kaposi's sarcoma-associated herpesvirus (KSHV) is one of the most common causes of cancer in this setting. KSHV infection of new cell targets is critical for tumor progression, and a better understanding of how viral receptors on the surface of cells are regulated in the tumor microenvironment may lead to new therapies. KSHV encodes unique RNAs called microRNAs (KSHV miRNAs) that regulate a variety of cell functions. In this study, we show that KSHV miRNAs increase the susceptibility of cells to KSHV infection and protect infected cells from death induced by cancer-promoting reactive nitrogen species (RNS). They accomplish this in large part by increasing cell surface expression of a transport protein subunit called xCT. We also show that KSHV miRNAs increase secretion of RNS by infected cells, and that blocking RNS secretion reduces the ability of KSHV to infect cells. Therefore, by regulating xCT and RNS, we find KSHV is able to “fine-tune” cell function in order to maintain a stable population of infected cells which secrete cancer-promoting factors in the local environment. This work has important implications for developing new therapies to target xCT and reduce survival of KSHV-infected tumor cells.</p>
</abstract><funding-group><funding-statement>This work was supported by grants from the National Institutes of Health (K08-1CA103858 to CP), the South Carolina COBRE for Oral Health (P20-RR-017696; CP is subproject investigator), an MUSC Hollings Cancer Center Translational Pilot Award (CP), a USUHS grant (R073NS to JK), and the MUSC Hollings Cancer Center (core grant P30-CA-138313 to the HCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="14"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Patients with immune deficiencies are at risk for life-threatening illnesses caused by herpesviruses, including the Kaposi's sarcoma-associated herpesvirus (KSHV). Bone marrow failure <xref ref-type="bibr" rid="ppat.1000742-Luppi1">[1]</xref>, lymphoproliferative syndromes <xref ref-type="bibr" rid="ppat.1000742-Soulier1">[2]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Cesarman1">[3]</xref>, and sarcoma <xref ref-type="bibr" rid="ppat.1000742-Chang1">[4]</xref> have all been etiologically linked to KSHV infection and occur with greater frequency in the setting of immune suppression related to HIV infection <xref ref-type="bibr" rid="ppat.1000742-Engels1">[5]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Bonnet1">[6]</xref> or organ transplantation <xref ref-type="bibr" rid="ppat.1000742-Lebbe1">[7]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Shepherd1">[8]</xref>. The most commonly encountered clinical manifestation of KSHV infection, Kaposi's sarcoma (KS), represents one of the most common tumors arising in the setting of HIV infection, one of the most common transplant-associated tumors, and a leading cause of morbidity and mortality <xref ref-type="bibr" rid="ppat.1000742-Engels1">[5]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Lebbe1">[7]</xref>. Moreover, KS is the most common tumor arising in the general population in some geographic areas <xref ref-type="bibr" rid="ppat.1000742-CookMozaffari1">[9]</xref>. Despite the reduced incidence of KS in the modern era of highly active antiretroviral therapy (HAART) <xref ref-type="bibr" rid="ppat.1000742-Vanni1">[10]</xref>, KS is increasingly recognized in HIV-infected patients with suppressed HIV viral loads and elevated CD4<sup>+</sup> T cell counts <xref ref-type="bibr" rid="ppat.1000742-Maurer1">[11]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Krown1">[12]</xref>. Clinical responses to cytotoxic agents for systemic KS vary widely in published trials, and these agents incur many side effects which may exacerbate or add to those already incurred by antiretroviral or immunosuppressive agents <xref ref-type="bibr" rid="ppat.1000742-Vanni1">[10]</xref>,<xref ref-type="bibr" rid="ppat.1000742-VonRoenn1">[13]</xref>. Given these shortcomings of existing therapies, novel targeted strategies are needed for the treatment or prevention of KS.</p>
<p>Published data support a role for KSHV-encoded genes in KS pathogenesis, including genes expressed primarily during lytic replication that facilitate angiogenesis and endothelial cell survival <xref ref-type="bibr" rid="ppat.1000742-Schulz1">[14]</xref>, and existing clinical data support this concept. An elevated KSHV viral load in the peripheral circulation predicts the onset and progression of both AIDS- and non-AIDS-related KS, and intralesional KSHV viral load correlates directly with tumor progression <xref ref-type="bibr" rid="ppat.1000742-Campbell1">[15]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Dupin1">[17]</xref>. One retrospective clinical study demonstrated that ganciclovir, a nucleoside analog that inhibits viral DNA polymerase activity and reduces KSHV replication <xref ref-type="bibr" rid="ppat.1000742-Kedes1">[18]</xref>, reduced the incidence of KS in patients receiving organ transplants <xref ref-type="bibr" rid="ppat.1000742-Martin1">[19]</xref>. In addition, KS arising in the setting of well-controlled HIV infection may be explained in part by reduced KSHV-specific immunity despite general immune recovery with HAART <xref ref-type="bibr" rid="ppat.1000742-Lambert1">[20]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Bihl1">[21]</xref>. Together, these data suggest a role for ongoing KSHV replication and infection of naïve target cells in the progression of KS. Interestingly, neither KS lesional spindle cells nor cultured endothelial cells infected by KSHV <italic>in vitro</italic> efficiently maintain viral episomes when passed in culture <xref ref-type="bibr" rid="ppat.1000742-Grundhoff1">[22]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Lebbe2">[23]</xref>, suggesting the potential importance of additional microenvironmental factors within KS tumors for facilitating KSHV infection.</p>
<p>The amino acid membrane transport system x<sub>c</sub><sup>−</sup> consists of a conserved heavy chain, 4F2hc, and an inducible subunit, xCT, that mediates amino acid exchange <xref ref-type="bibr" rid="ppat.1000742-Tsuchiya1">[24]</xref>. x<sub>c</sub><sup>−</sup> exchanges intracellular glutamate for extracellular cystine at the cell membrane, and the latter is rapidly reduced in the intracellular space to cysteine and incorporated into glutathione (GSH) and other protein biosynthesis pathways <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>. This allows for restoration of intracellular GSH stores and protection of x<sub>c</sub><sup>−</sup>-expressing cells from oxidative stress and cell death <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>. xCT expression is upregulated by physiological conditions that impact intracellular GSH levels, such as hypoxia, inflammation, and increased production of reactive species <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>. xCT was also recently identified as a fusion-entry receptor for KSHV and may mediate KSHV entry either in isolation or as part of a complex with other receptors for the virus <xref ref-type="bibr" rid="ppat.1000742-Kaleeba1">[26]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Veettil1">[27]</xref>. KSHV establishes infection within multiple xCT-expressing cell types that have been implicated in KS pathogenesis, including intralesional or circulating monocytes, intralesional macrophages, and endothelial cells <xref ref-type="bibr" rid="ppat.1000742-Kaleeba1">[26]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Rappocciolo1">[29]</xref>. However, whether KSHV itself also regulates xCT expression to promote viral infection of new cell targets or increase the longevity of KSHV-infected cells in the local environment is unknown.</p>
<p>miRNAs are small (19–23 nucleotides in length), non-coding RNAs that bind target mRNAs, marking them for degradation or post-transcriptional modification, and KSHV encodes 17 mature miRNAs which are expressed within KSHV-infected cells and KS lesions <xref ref-type="bibr" rid="ppat.1000742-Ganem1">[30]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Pfeffer1">[33]</xref>. xCT expression is regulated through competitive binding of positive and negative transcription factors to an “Antioxidant Response Element” (ARE) in the xCT promoter <xref ref-type="bibr" rid="ppat.1000742-Sasaki1">[34]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Ishii1">[35]</xref>, and existing data suggest that negative transcription regulators of ARE may be targeted by KSHV miRNAs <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Rodriguez1">[40]</xref>. Therefore, using cell culture systems employing macrophages and endothelial cells, we sought to determine whether KSHV miRNAs regulate the expression of xCT, and if so, whether this infuences cell permissiveness for KSHV infection and protection of infected cells from oxidative stress.</p>
</sec><sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>xCT is a principal determinant of macrophage permissiveness for KSHV infection</title>
<p>To first determine whether xCT expression correlates with macrophage susceptibility to KSHV infection, we utilized a BALB/c-derived murine macrophage cell line, 264.7 cells (“RAW” cells). We chose RAW cells given the recent demonstration of KSHV infection of murine macrophages <italic>in vivo</italic> <xref ref-type="bibr" rid="ppat.1000742-Parsons1">[41]</xref>, the identity (89%) and similarity (93%) of the murine xCT protein to its human counterpart <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>, and the utility of these cells for gene transfer studies. xCT expression is induced indirectly by substrates that compete for cystine uptake by xCT, like monosodium glutamate (Msg) <xref ref-type="bibr" rid="ppat.1000742-Gout1">[42]</xref> and sulfasalazine (Sul) <xref ref-type="bibr" rid="ppat.1000742-Gout2">[43]</xref>. We found that Msg or Sul significantly increased the number of RAW cells expressing the KSHV latency-associated nuclear antigen (LANA) following their incubation with purified KSHV (<xref ref-type="fig" rid="ppat-1000742-g001">Fig. 1A–E</xref>). This increase in the number of infected cells was reflected in an increase in viral episome copies for cells from Msg- and Sul-treated cultures (<xref ref-type="fig" rid="ppat-1000742-g001">Fig. 1F</xref>), although IFA suggested that the number of episomes (LANA dots) per cell was unchanged (<xref ref-type="fig" rid="ppat-1000742-g001">Fig. 1A–D</xref>). Msg and Sul also increased xCT transcript expression by RAW cells (<xref ref-type="fig" rid="ppat-1000742-g001">Fig. 1G</xref>), and direct targeting of xCT with siRNA significantly reduced the number of LANA-positive cells following RAW cell incubation with KSHV (<xref ref-type="fig" rid="ppat-1000742-g001">Fig. 1H and I</xref>). These data confirm the role of xCT as a principal determinant of RAW cell susceptibility to KSHV infection.</p>
<fig id="ppat-1000742-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g001</object-id><label>Figure 1</label><caption>
<title>xCT mediates KSHV infection of macrophages.</title>
<p>(<bold>A</bold>–<bold>D</bold>) 264.7 (“RAW”) cells were first incubated with Monosodium glutamate (Msg), Sulfasalazine (Sul) or vehicle control (DMSO) for 12 h followed by purified KSHV (K). 16 h later, IFA employing anti-LANA monoclonal antibodies and secondary antibodies conjugated to Texas Red were performed to identify expression of LANA signified by the typical punctate intranuclear expression pattern. Nuclei were identified using DAPI (blue). Some cells were incubated with UV-inactivated virus (UV-K) for negative controls. Representative images from one of three independent experiments are shown. (<bold>E</bold>) Relative infection rate was determined for groups in A–D as outlined in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>F</bold>) qPCR was used to determine relative intracellular KSHV DNA content normalized to the vehicle control group (relative viral copies) as explained in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>G</bold>) qRT-PCR was used to determine relative xCT transcript expression. (<bold>H</bold>) qRT-PCR was used to determine xCT transcript expression relative to control cells for cells transfected with either control (n) or xCT-specific siRNA. (<bold>I</bold>) Relative infection rates were calculated for groups in (H) using LANA IFA. For all assays, error bars represent the S.E.M. for three independent experiments. * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g001" xlink:type="simple"/></fig></sec><sec id="s2b">
<title>KSHV miRNAs regulate xCT expression and macrophage permissiveness for KSHV infection</title>
<p>To explore whether KSHV miRNAs regulate xCT expression, we co-transfected RAW cells with a construct encoding 10 of the 17 mature KSHV miRNAs described elsewhere <xref ref-type="bibr" rid="ppat.1000742-Samols2">[44]</xref>. Using semi-quantitative RT-PCR, we first confirmed upregulation of xCT with the collective expression of KSHV miRNAs encoded in the construct (<xref ref-type="fig" rid="ppat-1000742-g002">Fig. 2A</xref>). Using a KSHV miRNA target prediction algorithm validated previously <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>, we identified KSHV miRNA binding sites within 3'UTR of several murine genes associated with the regulation of xCT. The majority of binding sites were identified for 3 KSHV miRNAs: miR-K12-1, miR-K12-9, and miR-K12-11 (data not shown). To first determine whether these miRNAs were expressed within KSHV miRNA transfectants, we co-transfected cells with KSHV miRNAs and pGL3 luciferase reporter constructs encoding complimentary sequences for individual miRNAs (upon binding of pGL3 complimentary sequences to mature miRNAs, luciferase expression by pGL3 is repressed as shown elsewhere) <xref ref-type="bibr" rid="ppat.1000742-Samols2">[44]</xref>. This confirmed expression of miR-K12-1, miR-K12-9, and miR-K12-11 in these cells (<xref ref-type="fig" rid="ppat-1000742-g002">Fig. 2B</xref>). Next, using qRT-PCR, we found that miR-K12-1, miR-K12-9, and miR-K12-11 are responsible for the upregulation of xCT in KSHV miRNA transfectants since targeting these 3 miRNAs with specific 2'OMe RNA antagomirs entirely suppressed this effect (<xref ref-type="fig" rid="ppat-1000742-g002">Fig. 2C</xref>). Parallel experiments revealed that KSHV miRNAs increase intracellular KSHV viral load and viral transcript expression within macrophages following their incubation with KSHV (<xref ref-type="fig" rid="ppat-1000742-g003">Fig. 3A and B</xref>). Once again, this effect was entirely suppressed by targeting miR-K12-1, miR-K12-9, and miR-K12-11 (<xref ref-type="fig" rid="ppat-1000742-g003">Fig. 3A and B</xref>). In addition, we found that siRNA targeting of xCT significantly suppressed the KSHV miRNA-mediated increase in macrophage susceptibility to KSHV infection (<xref ref-type="fig" rid="ppat-1000742-g003">Fig. 3C</xref>).</p>
<fig id="ppat-1000742-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g002</object-id><label>Figure 2</label><caption>
<title>KSHV miRNAs upregulate xCT expression by macrophages.</title>
<p>(<bold>A</bold>) RT-PCR was used to determine expression of xCT transcripts in RAW cells transfected with either control (pc) or miRNA-expressing vectors (pc-miRNA). β-actin was used as a loading control. (<bold>B</bold>) RAW cells were co-transfected with miRNA luciferase reporter constructs (pGL3-miX where X = complimentary sequence for the individual KSHV miRNAs noted) and either control or miRNA-expressing vectors. 48 h later, luciferase expression was determined for miRNA transfectants relative to controls (RLU). (<bold>C</bold>) Cells were transfected with control or miRNA-expressing vectors with or without 2'OMe RNA antagomirs targeting miR-K12-1, miR-K12-9, and miR-K12-11 (mi1/9/11). 48 h following subsequent incubation with KSHV (K), qRT-PCR was used to determine relative xCT transcript expression. For all assays, error bars represent the S.E.M. for three independent experiments. * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g002" xlink:type="simple"/></fig><fig id="ppat-1000742-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g003</object-id><label>Figure 3</label><caption>
<title>KSHV miRNA upregulation of xCT increases macrophage susceptibility to KSHV infection.</title>
<p>(<bold>A</bold>) RAW cells were transfected with control or miRNA-expressing vectors then incubated with purified KSHV (K). LANA IFA were performed 16 h later, and relative infection rates were determined as outlined in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>B</bold>) qPCR was used to determine relative intracellular KSHV DNA content for groups in A. (<bold>C</bold>) Cells were co-transfected with control or miRNA-expressing vectors and either control (n) or xCT-specific siRNA then incubated with purified KSHV. 16 h later, LANA IFA were used to determine relative infection rates. For all assays, error bars represent the S.E.M. for three independent experiments. * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g003" xlink:type="simple"/></fig></sec><sec id="s2c">
<title>KSHV miR-K12-11 suppresses BACH-1 to induce xCT expression and cell permissiveness for KSHV infection in macrophages and endothelial cells</title>
<p>Our bioinformatics analyses revealed putative binding sites for miR-K12-11 within the 3'UTR of the murine BACH-1 gene (<xref ref-type="fig" rid="ppat-1000742-g004">Fig. 4A</xref>). We subsequently confirmed KSHV miRNA suppression of BACH-1 within RAW cells, an effect largely reversed through direct targeting of KSHV miR-K12-11 (<xref ref-type="fig" rid="ppat-1000742-g004">Fig. 4B</xref>). In addition, direct siRNA targeting of BACH-1 significantly increased basal levels of xCT expression in these cells (<xref ref-type="fig" rid="ppat-1000742-g004">Fig. 4C–E</xref>) as well as macrophage permissiveness to KSHV infection (<xref ref-type="fig" rid="ppat-1000742-g004">Fig. 4F</xref>), although to a lesser degree than the collective expression of miR-K12-1, miR-K12-9, and miR-K12-11 (<xref ref-type="fig" rid="ppat-1000742-g003">Fig. 3</xref>).</p>
<fig id="ppat-1000742-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g004</object-id><label>Figure 4</label><caption>
<title>KSHV miRNAs upregulate xCT expression through repression of BACH-1.</title>
<p>(<bold>A</bold>) Potential KSHV miRNA binding sites were identified within the 3'UTR of murine BACH-1 using an ad-hoc scanning program as described in <xref ref-type="sec" rid="s4">Methods</xref>. miR-K12-11 nucleotides with matching base pairs depicted in capital letters bind within positions 2318–2339 and 2530–2551. (<bold>B</bold>) RAW cells were transfected with 1 µg control or miRNA-expressing vectors with or without 300 pmol of 2'OMe RNA antagomirs targeting miR-K12-11. 48 h later, BACH-1 expression was quantified by Western blot. β-Actin was used for loading controls. Numbers represent immunoreactivity relative to control transfectants as quantified using Image-J software. (<bold>C–D</bold>) RT-PCR (C) and qRT-PCR (D) were used to quantify transcripts for BACH-1 (C) and xCT (C and D), respectively, in controls cells or cells transfected with either control (n) or BACH-1-specific siRNA. (<bold>E</bold>) Western blots were used to quantify BACH-1 protein expression in siRNA-transfected cells for groups in (C). Immunoreactivity was quantified as in (B). (<bold>F</bold>) Cells were transfected with control or BACH-1 siRNA as above and subsequently incubated with KSHV. Relative infection rates were determined 12 h later using LANA IFA. Error bars represent the S.E.M. for three independent experiments. * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g004" xlink:type="simple"/></fig>
<p>Published data have confirmed direct targeting of BACH-1 by miR-K12-11 in human cells <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>. To validate our observations and to determine their broader significance for human cells with known relevance to KS pathogenesis, we repeated our experiments using primary human umbilical vein endothelial cells (HUVEC). We found that Msg, Sul or KSHV miRNA transfection significantly increased xCT transcript expression and, based on IFA, KSHV episome copy number <italic>per cell</italic> following subsequent <italic>de novo</italic> infection (<xref ref-type="fig" rid="ppat-1000742-g005">Fig. 5A–J</xref>). In contrast to what was observed for RAW cells, IFA indicated that the total number of infected HUVEC remained unchanged with these interventions (<xref ref-type="supplementary-material" rid="ppat.1000742.s001">Fig. S1</xref>). In addition, either direct suppression of xCT by siRNA or concurrent inhibition of miR-K12-11 reduced xCT expression and intracellular viral load in KSHV miRNA transfectants (<xref ref-type="fig" rid="ppat-1000742-g005">Fig. 5H–J</xref>). Collective expression of KSHV miRNAs also reduced BACH-1 expression in HUVEC, an effect suppressed with concurrent inhibition of miR-K12-11 (<xref ref-type="fig" rid="ppat-1000742-g005">Fig. 5K</xref>).</p>
<fig id="ppat-1000742-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g005</object-id><label>Figure 5</label><caption>
<title>miR-K12-11 suppresses BACH-1 expression and increases endothelial cell susceptibility to KSHV through upregulation of xCT.</title>
<p>(<bold>A–G</bold>) HUVEC were incubated with vehicle control (DMSO), Msg, or Sul for 12 h followed by purified KSHV (K) using an MOI∼0.5–1. 16 h later, LANA IFA were performed as previously described. (A–D) Representative images from one of three independent experiments are shown. (<bold>H–K</bold>) HUVEC were transfected with control or miRNA-expressing vectors along with a 2'OMe RNA antagomir for miR-K12-11 or either control (n) or xCT-specific siRNA. (<bold>E</bold>,<bold>H</bold>) Relative LANA expression was determined as described in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>F</bold>,<bold>I</bold>) qRT-PCR was used to determine relative xCT transcript expression. (<bold>G</bold>,<bold>J</bold>) qPCR was used to determine relative intracellular KSHV DNA content normalized to controls. (<bold>K</bold>) Western blots were used to identify BACH-1 protein expression and immunoreactivity quantified as previously described. For all assays, error bars represent the S.E.M. for three independent experiments. * = p&lt;0.05, * * = p&lt;0.01 (For Fig. H–J, comparisons are relative to either pc-miRNA or pc-miRNA+K).</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g005" xlink:type="simple"/></fig></sec><sec id="s2d">
<title>KSHV miRNAs upregulate macrophage secretion of reactive nitrogen species (RNS) and protect macrophages from RNS-induced cell death</title>
<p>xCT restoration of intracellular glutathione and increased scavenging of free radicals reduces cell death resulting from nitration of proteins, lipids, and nucleic acids by RNS <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Guidarelli1">[45]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Frey1">[46]</xref>. Because we observed increased xCT expression induced by KSHV miRNAs, we hypothesized that KSHV may also increase RNS secretion by macrophages and that xCT upregulation would serve as an auto-protective mechanism in this environment. Using a standard Greiss reaction assay for quantifying nitrite in culture supernatants as a surrogate measure of RNS secretion, we found that KSHV infection of RAW cells induced a ∼20-fold increase in RNS secretion and that the majority of this effect was mediated through the collective expression of miR-K12-1, miR-K12-9, and miR-K12-11 (<xref ref-type="fig" rid="ppat-1000742-g006">Fig. 6A</xref>). A similar pattern was observed following overexpression of KSHV miRNAs (<xref ref-type="fig" rid="ppat-1000742-g006">Fig. 6B and C</xref>). Non-specific TLR activation, as might be initiated by mature miRNAs or their precursors, is capable of inducing RNS production <xref ref-type="bibr" rid="ppat.1000742-Lambeth1">[47]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Asehnoune1">[48]</xref>. However, specific inhibitors of MyD88-independent and -dependent toll-like receptor (TLR) pathways failed to reduce induction of RNS secretion by KSHV miRNAs, suggesting that this effect is not mediated through TLR activation (<xref ref-type="supplementary-material" rid="ppat.1000742.s002">Fig. S2</xref>).</p>
<fig id="ppat-1000742-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g006</object-id><label>Figure 6</label><caption>
<title>KSHV miRNAs induce reactive nitrogen species (RNS) secretion by macrophages.</title>
<p>(<bold>A</bold>) RAW cells were transfected with 2'OMe RNA antagomirs targeting miR-K12-1, miR-K12-9, and miR-K12-11 or all three together (mi1/9/11). Cells were subsequently incubated with purified KSHV (K) and nitrite quantified within culture supernatants as described in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>B</bold>) Cells were transfected with control or miRNA-expressing vectors and nitrite quantified within culture supernatants at the times indicated. (<bold>C</bold>) Cells were co-transfected with either control or miRNA-expression constructs without (mock) or with specific 2'OMe RNA antagomirs. As an additional control, some cells were transfected with an antagomir targeting miR-K12-12 which is not expressed by the miRNA-expressing construct. For all assays, error bars represent the S.E.M. for three independent experiments. * = p&lt;0.05, * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g006" xlink:type="simple"/></fig>
<p>To determine whether upregulation of xCT by KSHV miRNAs offers a protective mechanism for macrophages in an environment rich in RNS, we first established that provision of the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP) <xref ref-type="bibr" rid="ppat.1000742-Lee1">[49]</xref> increased RNS concentrations within RAW cell culture supernatants and induced cell death in a dose-dependent manner (<xref ref-type="fig" rid="ppat-1000742-g007">Fig. 7A and B</xref>). Subsequently, we found that either KSHV infection or overexpression of KSHV miRNAs significantly increased macrophage resistance to SNAP-induced cell death. Moreover, siRNA experiments confirmed that this effect was mediated primarily through the upregulation of xCT (<xref ref-type="fig" rid="ppat-1000742-g007">Figs. 7C and D</xref>).</p>
<fig id="ppat-1000742-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g007</object-id><label>Figure 7</label><caption>
<title>KSHV miRNAs enhance macrophage survival in an environment of oxidative stress through the upregulation of xCT.</title>
<p>(<bold>A</bold>) RAW cells were treated with the indicated concentrations of SNAP or vehicle control for 12 h prior to nitrite quantification within culture supernatants. (<bold>B</bold>) Relative cell viability was determined for groups in (A) as described in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>C</bold>) Cells were transfected with either control (n) or xCT-specific (x) siRNA and incubated with UV-K (KSHV−) or KSHV (KSHV+) 48 h later. (<bold>D</bold>) Cells were co-transfected with xCT siRNA and either control or miRNA-expressing vectors for 48 h, then incubated for an additional 12 h with SNAP prior to viability determinations. For all assays, error bars represent the S.E.M. for three independent experiments. * = p&lt;0.05, * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g007" xlink:type="simple"/></fig></sec><sec id="s2e">
<title>RNS facilitate KSHV infection of macrophages</title>
<p>RNS are expressed within KS lesions <xref ref-type="bibr" rid="ppat.1000742-Mallery1">[50]</xref>, but whether RNS themselves influence <italic>de novo</italic> KSHV infection is unknown. To reduce macrophage secretion of RNS, we incubated RAW cells with L-N<sup>6</sup>-monomethyl-arginine (L-NMMA), an inhibitor of all forms of nitric oxide synthase (NOS) <xref ref-type="bibr" rid="ppat.1000742-Alexander1">[51]</xref> that induces no discernable toxicity for RAW cells over a wide range of concentrations (<xref ref-type="supplementary-material" rid="ppat.1000742.s003">Fig. S3</xref>). Interestingly, L-NMMA significantly reduced secretion of RNS initiated by KSHV miRNAs and reduced <italic>de novo</italic> KSHV infection of macrophages in a dose-dependent manner (<xref ref-type="fig" rid="ppat-1000742-g008">Fig. 8</xref>), suggesting a role for NOS and RNS in facilitating <italic>de novo</italic> KSHV infection.</p>
<fig id="ppat-1000742-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g008</object-id><label>Figure 8</label><caption>
<title>RNS inhibition reduces macrophage susceptibility to KSHV infection.</title>
<p>(<bold>A</bold>) RAW cells were first transfected with 1 µg of either control or miRNA-expressing vectors then incubated with L-NMMA for 12 h prior to nitrite quantification in culture supernatants. (<bold>B</bold>) Cells were incubated with L-NMMA for 12 h prior to their incubation with purified KSHV (K) for 2 h. Following an additional 12 h, LANA IFA were performed and relative infection rates determined as described in <xref ref-type="sec" rid="s4">Methods</xref>. (<bold>C</bold>) qPCR was used to determine relative intracellular KSHV DNA content for KSHV-infected cells pre-treated with either vehicle or 0.5mM L-NMMA. In all assays, error bars represent the S.E.M. for three independent experiments. * = p&lt;0.05, * * = p&lt;0.01.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g008" xlink:type="simple"/></fig></sec><sec id="s2f">
<title>xCT expression is increased within more advanced KS lesions</title>
<p>KSHV miRNAs are expressed within KS lesions <xref ref-type="bibr" rid="ppat.1000742-Ganem1">[30]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Samols1">[32]</xref> but to our knowledge, expression of xCT within KS tissue has never been demonstrated. To address this, we used immunohistochemistry to quantify xCT expression within KS skin lesions representing the full spectrum of histopathologic progression of KS. We found that stage I tumors (patches) and stage II tumors (plaques) exhibited either no or minimally discernable xCT expression, respectively (<xref ref-type="fig" rid="ppat-1000742-g009">Fig. 9</xref>). In contrast, stage III tumors (nodules) exhibited easily discernable membrane expression of xCT by the majority of cells in these lesions, including nearly all spindle-shaped cells (<xref ref-type="fig" rid="ppat-1000742-g009">Fig. 9</xref>). Moreover, we confirmed that stage III tumors exhibited significantly more LANA<sup>+</sup> cells than stage I lesions (<xref ref-type="supplementary-material" rid="ppat.1000742.s004">Fig. S4</xref>) in agreement with published data <xref ref-type="bibr" rid="ppat.1000742-Pak1">[52]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Pyakurel1">[53]</xref> as well as our observed correlation between KSHV viral load and xCT expression in our <italic>in vitro</italic> experiments.</p>
<fig id="ppat-1000742-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1000742.g009</object-id><label>Figure 9</label><caption>
<title>xCT expression within KS lesions correlates with tumor stage.</title>
<p>KS diagnosis and histopathologic staging were independently confirmed by a dermatopathologist using hematoxylin and eosin (H &amp; E). Tumors were then processed for immunohistochemistry as described in <xref ref-type="sec" rid="s2">Methods</xref> using either pre-immune sera (control) or xCT anti-sera. xCT expression is revealed by dark brown membrane-associated staining in contrast to blue nuclear staining. Representative images from all stages (I = patch, II = plaque, III = nodule) are shown, including two different stage III tumors (A and B). All images are shown at original magnification ×20 or 60.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.g009" xlink:type="simple"/></fig></sec></sec><sec id="s3">
<title>Discussion</title>
<p>In this study, we found that KSHV-encoded miR-K12-11 upregulates the expression of xCT in macrophages and endothelial cells, in part through suppression of a negative regulator of gene transcription, BACH-1. We also found that KSHV miRNAs induce macrophage secretion of RNS and protect these cells from RNS-induced cell death through the upregulation of xCT. Moreover, reducing NOS activity and RNS secretion by macrophages reduces their permissiveness for KSHV. Finally, we found that cells within more advanced human KS tumors express more xCT than cells from early-stage lesions. We hypothesize, therefore, that KSHV miRNAs facilitate KS pathogenesis through cooperative mechanisms that regulate xCT and RNS secretion to promote ongoing <italic>de novo</italic> infection and survival of infected cells in the tumor microenvironment.</p>
<sec id="s3a">
<title>Implications of the regulation of BACH-1, xCT expression, and cell susceptibility to KSHV infection by KSHV miRNAs</title>
<p>xCT expression is differentially regulated during oxidative stress through transcription factor binding to the <italic>cis</italic>-acting ARE in its promoter <xref ref-type="bibr" rid="ppat.1000742-Sasaki1">[34]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Ishii1">[35]</xref>. Transcription factors that bind to the ARE include a positive regulator known as Nuclear factor erythroid 2-related factor-2 (Nrf-2) <xref ref-type="bibr" rid="ppat.1000742-Ishii1">[35]</xref> and negative regulators, including BACH-1 and c-Maf, which competitively reduce Nrf-2 binding to the ARE thereby repressing ARE-mediated gene expression <xref ref-type="bibr" rid="ppat.1000742-Dhakshinamoorthy1">[37]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Dhakshinamoorthy2">[38]</xref>. KSHV miRNAs are expressed within KSHV-infected cells and KS lesions <xref ref-type="bibr" rid="ppat.1000742-Ganem1">[30]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Samols1">[32]</xref>, and existing data suggest that both BACH-1 and c-Maf are targeted by KSHV miRNAs <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Hong1">[39]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Rodriguez1">[40]</xref>. More specifically, KSHV miR-K12-11, an ortholog of cellular miR-155, targets and reduces expression of BACH-1 <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>. miR-155 downregulates c-Maf expression by T cells <xref ref-type="bibr" rid="ppat.1000742-Rodriguez1">[40]</xref>, and KSHV miRNAs downregulate c-Maf expression in endothelial cells <xref ref-type="bibr" rid="ppat.1000742-Hong1">[39]</xref>. Therefore, we hypothesized that miR-K12-11, in cooperation with other KSHV miRNAs, regulates xCT expression.</p>
<p>We found that miR-K12-11 downregulated BACH-1 and induced xCT expression in both macrophages and endothelial cells, although additional experiments using site-directed mutagenesis are needed to confirm direct interactions between BACH-1 and the xCT ARE in murine cells. Further validating our findings, we found that BACH-1 targeting by siRNA increased macrophage permissiveness for infection by approximately 70% (<xref ref-type="fig" rid="ppat-1000742-g004">Fig. 4F</xref>), although overexpression of multiple miRNAs increased permissiveness by approximately 250% (<xref ref-type="fig" rid="ppat-1000742-g003">Fig. 3E</xref>). Differences in transfection efficiency for siRNA and the KSHV miRNA constructs could be partially responsible for this discrepancy, but we hypothesize that it is due in part to the effect of multiple KSHV miRNAs, including miR-K12-1 and miR-K12-9, and the cooperative targeting of multiple genes. Our initial screen for KSHV miRNA binding sites within murine and human genes known to regulate xCT expression and RNS secretion revealed multiple binding sites for miR-K12-1, miR-K12-9 and miR-K12-11 (data not shown). These analyses also revealed binding sites for miR-K12-4, although not miR-K12-1 or miR-K12-9, within both murine and human BACH-1 3'UTR sequences (not shown), although we have not yet confirmed the functional impact of miR-K12-4 expression on BACH-1 or xCT expression. Additional studies are needed to confirm direct targeting of BACH-1 or other genes by these KSHV miRNAs and to characterize the functional impact of this targeting for expression of xCT and other ARE-containing genes regulated by BACH-1, including those involved in the generation of RNS (see below).</p>
<p>To our knowledge, these data are the first to suggest a role for a herpesvirus in the autocrine upregulation of its own receptor, although whether increased cell permissiveness for KSHV entry following initial infection and miRNA expression is “accidental” or “purposeful” in the context of KSHV-host evolution remains debatable. In addition to promoting cell survival (see below), autocrine upregulation of xCT may provide evolutionary advantages for the virus achieved through an increase in intracellular viral load that were not addressed by our studies. This concept is supported by several reports revealing that a significant proportion of KSHV-infected tumor cells, including those within KS lesions, contain multiple viral clones <xref ref-type="bibr" rid="ppat.1000742-Gill1">[54]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Boulanger1">[56]</xref>. Another study showed that the downregulation of MHC Class I (MHC-I) in KSHV-infected cells is directly proportional to the level of expression of the KSHV modulator of immune recognition 2 (MIR2) and intracellular KSHV episome copy number <xref ref-type="bibr" rid="ppat.1000742-Adang1">[57]</xref>, implying that increasing intracellular viral copies may promote reduced KSHV epitope presentation to CD8<sup>+</sup> T cells as a mechanism for immune evasion. Our IFA indicated that for RAW cells, miRNA upregulation of xCT increased the permissiveness of uninfected cells for KSHV, although not viral episome copies within individual cells. In contrast, miRNA upregulation of xCT increased HUVEC viral episome copies per cell following subsequent infection, although not the total number of infected cells. Our studies did not directly address whether the observed increase in episome copies per cell for HUVEC is the result of intracellular episome replication or “superinfection” with exogenous virions. Experiments utilizing limiting dilution PCR <xref ref-type="bibr" rid="ppat.1000742-Babcock1">[58]</xref> or single cell imaging techniques <xref ref-type="bibr" rid="ppat.1000742-Parsons1">[41]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Adang2">[59]</xref> could be used to confirm whether intracellular KSHV viral load and miRNA expression correlate with xCT expression on a single cell level and to address the possibility that KSHV miRNA upregulation of xCT increases cell permissiveness for subsequent virion entry. It is interesting to speculate whether autocrine regulation of surface receptors by KSHV miRNAs differs depending on the cell type, and whether soluble factors released by infected cells differentially influence xCT expression for different cell types.</p>
</sec><sec id="s3b">
<title>Implications of the regulation of RNS secretion, xCT expression, and survival of KSHV-infected cells by KSHV miRNAs</title>
<p>Our data indicate a role for KSHV miRNAs in the induction of RNS secretion and the protection of cells from RNS-induced cell death through the upregulation of xCT. Of additional relevance, we found that L-NMMA, an inhibitor of NOS, reduced KSHV miRNA-induced secretion of RNS and <italic>de novo</italic> KSHV infection. Additional studies are currently underway to elucidate the mechanism for these observations. Through the nitration of either extracellular or intracellular proteins, RNS activate Nrf-2 <xref ref-type="bibr" rid="ppat.1000742-Sasaki1">[34]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Ishii1">[35]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Zhu1">[60]</xref> and, therefore, may upregulate xCT expression through both autocrine and paracrine mechanisms. It is also conceivable that miR-K12-11 downregulation of BACH-1 increases expression of other ARE-containing genes involved in the induction of RNS or the protection of cells from oxidative stress, including heme oxygenase-1 (HO-1) <xref ref-type="bibr" rid="ppat.1000742-Sasaki1">[34]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Ishii1">[35]</xref>. Interestingly, HO-1 is expressed within KS lesions, and KSHV infection of endothelial cells induces activation of HO-1 <xref ref-type="bibr" rid="ppat.1000742-McAllister1">[61]</xref>. It is probable that RNS secretion and downstream consequences are mediated through the collective targeting of multiple genes by KSHV miRNAs, and that this may occur within a variety of KSHV-infected cells with the capacity to secrete RNS, including endothelial cells and dendritic cells <xref ref-type="bibr" rid="ppat.1000742-Lo1">[25]</xref>. Characterization of miRNA regulation of RNS for a broader array of cell types relevant to KS pathogenesis is underway. Furthermore, our studies do not address whether KSHV miRNAs regulate secretion of reactive oxygen species (ROS) by infected cells, and it is conceivable that ROS play a role in the paracrine regulation of xCT or other events pertaining to KSHV infection. Studies are ongoing in our laboratory to define the relative importance of specific reactive species in the regulation of xCT expression and KSHV dissemination in the microenvironment.</p>
<p>Multiple studies implicate RNS in KS pathogenesis <xref ref-type="bibr" rid="ppat.1000742-Frey1">[46]</xref>, <xref ref-type="bibr" rid="ppat.1000742-Mallery1">[50]</xref>, <xref ref-type="bibr" rid="ppat.1000742-Weninger1">[62]</xref>–<xref ref-type="bibr" rid="ppat.1000742-Ma1">[66]</xref>. RNS and NOS are expressed within KS lesions <xref ref-type="bibr" rid="ppat.1000742-Mallery1">[50]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Weninger1">[62]</xref>, and RNS induce endothelial cell migration, proliferation and angiogenesis <xref ref-type="bibr" rid="ppat.1000742-Frey1">[46]</xref> as well as T cell apoptosis <xref ref-type="bibr" rid="ppat.1000742-Pyo1">[63]</xref>. Moreover, existing data support a role for KSHV in the regulation of superoxide dismutase (SOD) in the KS microenvironment <xref ref-type="bibr" rid="ppat.1000742-Mallery1">[50]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Thurau1">[67]</xref>, and cytokines associated with KS pathogenesis have been implicated in the activation of RNS secretion by macrophages <xref ref-type="bibr" rid="ppat.1000742-Yanagisawa1">[64]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Kim1">[65]</xref>. Interestingly, a recent publication demonstrated that Rac1 transgenic mice overexpressing NADPH-oxidase-dependent reactive species developed KS-like lesions and that systemic administration of the antioxidant N-acetylcysteine reduced KS formation in this model <xref ref-type="bibr" rid="ppat.1000742-Ma1">[66]</xref>. Preliminary experiments performed in our laboratory have revealed that inhibition of NADPH-oxidase using diphenylene iodonium (DPI) also reduces KSHV miRNA-induced RNS secretion and infection of naïve cells (data not shown). In addition, at least one study has implicated cellular miRNAs in the regulation of Rac1 <xref ref-type="bibr" rid="ppat.1000742-Yu1">[68]</xref>. Therefore, our findings have important implications for paracrine regulation of cellular events pertaining to KS pathogenesis, and systemic inhibition of RNS may interfere with many of these events including viral dissemination and angiogenesis.</p>
</sec><sec id="s3c">
<title>Clinical implications of xCT expression within KS lesions</title>
<p>We have demonstrated that xCT is expressed to a greater extent within more advanced KS lesions containing a greater number of KSHV-infected cells. To our knowledge, these are the first data to demonstrate xCT expression in clinical samples from KSHV-infected patients and are consistent with published data documenting higher KSHV intratumoral viral loads within more advanced KS lesions <xref ref-type="bibr" rid="ppat.1000742-Pak1">[52]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Pyakurel1">[53]</xref>. Importantly, they also support our hypothesis that KSHV upregulation of xCT facilitates expansion of the KSHV reservoir in the microenvironment and KS progression. Moreover, our observation that spindle-shaped cells within stage III tumors express xCT is consistent with our data revealing upregulation of xCT and KSHV permissiveness for endothelial cells <italic>in vitro</italic> by KSHV miRNAs. Additional studies are needed to confirm whether KSHV miRNAs, BACH-1 and other putative xCT regulatory factors are differentially expressed during different stages of KS progression. Future translational studies may also shed light on whether quantifying xCT in clinical samples provides additional prognostic information for patients at risk for KS, and whether targeting xCT or its regulatory pathways will offer a useful approach for the treatment or prevention of this disease.</p>
</sec></sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Cell culture</title>
<p>BCBL-1 cells were grown in RPMI 1640 media (Gibco) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES (pH 7.5), 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, 0.05 mM β-mercaptoethanol, and 0.02% (wt/vol) sodium bicarbonate. Murine macrophages, RAW 264.7 cells (RAW cells), were obtained from American Type Culture Collection (ATCC) and grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% FBS. HeLa cells were grown in DMEM supplemented with 10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. Human umbilical vein endothelial cells (HUVEC) were grown in DMEM/F-12 50/50 medium (Cellgro) supplemented with 5% FBS and 0.001 mg/mL Puromycin (Sigma).</p>
</sec><sec id="s4b">
<title>Antibodies and reagents</title>
<p>Antibodies recognizing BACH-1 (H-130) and β-Actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Sigma (St. Louis, MO), respectively. Msg, Sul and L-NMMA were purchased from Sigma (St. Louis, MO). SNAP was purchased from Invitrogen (Eugene, Oregon).</p>
</sec><sec id="s4c">
<title>Transfection assays</title>
<p>A 2.8 Kbp construct encoding 10 individual KSHV microRNAs (pcDNA-miRNA, containing miR-K12-1/2/3/4/5/6/7/8/9/11), and luciferase reporter constructs encoding complimentary sequences for individual miRNA (pGL3-miRNA sensors), have been validated previously in transfection assays for expression of KSHV miRNAs <xref ref-type="bibr" rid="ppat.1000742-Samols2">[44]</xref>. These constructs were used to transiently transfect RAW cells and HUVEC. For inhibition of mature miRNAs, 2'OMe RNA antagomirs were designed and purchased from Dharmacon (Chicago, IL) as previously described <xref ref-type="bibr" rid="ppat.1000742-Samols2">[44]</xref>. BACH-1, xCT, and non-target (control) siRNAs (ON-TARGET plus SMART pool) were also purchased from Dharmacon. Cells were transfected with 1 µg pcDNA-miRNA, 0.5 µg pGL3-miRNA sensors, 300 pmol 2'OMe RNA antagomirs, siRNAs, and/or 1 µg pcDNA for negative controls in 12-well plates using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and/or DharmaFECT Transfection Reagent (Dharmacon, Chicago, IL) for 48 h prior to their incubation with KSHV. For miRNA inhibitor assays, control cells were transfected with a 2'OMe RNA antagomir targeting miR-K12-12, a KSHV miRNA not encoded by the pcDNA-miRNA construct. For luciferase expression assays, cells were incubated with 100 µL lysis buffer (Promega, Madison, WI), and luciferase activity determined within lysates using a Berthold FB12 luminometer (Titertek, Huntsville, AL). Light units were normalized to total protein levels for each sample using the BCA protein assay kit according to the manufacturer's instructions (Pierce, Rockford, IL). Transfection efficiency was assessed through co-transfection of a lacZ reporter construct kindly provided by Dr. Yusuf Hannun (Medical University of South Carolina, Charleston, SC), and β-galactosidase activity determined using a commercially available β-galactosidase enzyme assay system according to the manufacturer's instructions (Promega, Madison, WI). 3 independent transfections were performed for each experiment, and all samples were analyzed in triplicate for each transfection.</p>
</sec><sec id="s4d">
<title>Nitrite quantification</title>
<p>Nitrite concentrations within culture supernatants were determined using the Griess Reagent System (Promega, Madison, WI) according to the manufacturer's instructions.</p>
</sec><sec id="s4e">
<title>Immunoblotting</title>
<p>Cells were lysed in buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1% NP40, 1 mM EDTA, 5 mM NaF and 5 mM Na<sub>3</sub>VO<sub>4</sub>. 30 µg of total cell lysate was resolved by SDS–10% PAGE and transferred to nitrocellulose membranes prior to incubation with antibodies for proteins of interest as well as β-Actin for loading controls. Immunoreactive bands were developed by enhanced chemiluminescence reaction (Perkin-Elmer), visualized by autoradiography, and quantified using Image-J software.</p>
</sec><sec id="s4f">
<title>Bioinformatics analysis</title>
<p>The 3'UTR sequences of BACH-1 and other RNS-associated genes were obtained from Ensembl (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org" xlink:type="simple">http://www.ensembl.org</ext-link>). 3'UTRs were analyzed to extract all potential KSHV miRNA binding sites using an ad-hoc scanning program specifically developed to assess 3'UTR KSHV miRNA seed sequence matching, as validated previously <xref ref-type="bibr" rid="ppat.1000742-Skalsky1">[36]</xref>.</p>
</sec><sec id="s4g">
<title>KSHV purification and infection</title>
<p>BCBL-1 cells were incubated with 0.6 mM valproic acid for 4–6 days, and KSHV was purified from culture supernatants by ultracentrifugation at 20,000×g for 3 h, 4°C. The viral pellet was resuspended in 1/100 the original volume in the appropriate culture media, and aliquots were frozen at −80°C. Target cells were incubated with concentrated virus in the presence of 8 µg/mL polybrene (Sigma-Aldrich) for 2 h at 37°C. Inactivated KSHV used for negative controls was prepared by incubating viral stocks with ultraviolet (UV) light (1200 J/cm<sup>2</sup>) for 10′ in a CL-1000 Ultraviolet Crosslinker (UVP). The concentration of infectious viral particles used in each experiment (multiplicity of infection [MOI]) was calculated as previously described <xref ref-type="bibr" rid="ppat.1000742-Adang1">[57]</xref>,<xref ref-type="bibr" rid="ppat.1000742-Tomescu1">[69]</xref>.</p>
</sec><sec id="s4h">
<title>Immunofluorescence assays and determination of relative infection rates</title>
<p>1×10<sup>4</sup> RAW cells or HUVEC were seeded per well in eight-well chamber slides (Thermo Fisher, Rochester, NY) and incubated with viral stocks (MOI∼10 for RAW cells, MOI∼0.1–1 for HUVEC) in the presence of 8 µg/mL polybrene (Sigma-Aldrich) for 2 h at 37°C. 16 h later, cells were fixed and permeabilized following incubation with 1∶1 methanol-acetone for 10′ at −20°C. To reduce non-specific staining, slides were incubated in blocking reagent (10% normal goat serum, 3% bovine serum albumin, and 1% glycine) for 30′. To identify expression of the latency-associated nuclear antigen (LANA) of KSHV, cells were subsequently incubated with 1∶1000 dilution of an anti-LANA rat monoclonal antibody (ABI) for 1 h, followed by a goat anti-rat secondary antibody (1∶100) conjugated to Texas Red (Invitrogen) for 1 h at 25°C. Nuclei were subsequently counterstained with 0.5 µg/mL 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) in 180 mM Tris-HCl (pH 7.5). Slides were examined at 60× magnification using a Nikon TE2000-E fluorescence microscope. Infection rates were determined following examination of at least 200 cells from within 5∼6 random fields in each group. For RAW cell experiments, comparisons between groups are reported as relative infections rates, where relative infection rate = # infected cells per 200 cells in experimental group/infected cells per 200 cells in control group. For RAW cell experiments, comparisons between groups are reported as relative infections rates, where relative infection rate = # infected cells per 200 cells in experimental group/# infected cells per 200 cells in control group. Since HUVEC are more permissive for infection and the majority of cells exhibit at least 1–2 LANA dots (episomes) at MOI∼1, we calculated relative LANA expression for HUVEC experiments as follows: relative LANA expression = # LANA dots per 200 cells in experimental group/# LANA dots per 200 cells in control group.</p>
</sec><sec id="s4i">
<title>Biochemical assays</title>
<p>1×10<sup>4</sup> RAW cells or HUVEC were seeded per well in eight-well chamber slides and incubated with 10 mM Msg, 0.3 mM Sul or 0.01–1.0 mM L-NMMA for 12 h at 37°C, then incubated with cell-free KSHV for 2 h at 37°C. After 12 h, LANA expression within RAW cells was determined by IFA as outlined above.</p>
</sec><sec id="s4j">
<title>Toll-like receptor inhibition</title>
<p>RAW cells were transfected with 1 µg of pcDNA-miRNA or empty vector control, and after 24 h, incubated with 10 mM of either drug vehicle or a double-stranded RNA-activated protein kinase (PKR) inhibitor 2-Aminopurine (InvivoGen, San Diego, CA) for an additional 3 h. In parallel experiments, transfectants were incubated with 100 µM of MyD88 inhibitory peptide or control peptide (Imgenex, San Diego, CA) for an additional 24 h. Nitrite concentration was quantified within culture supernatants as detailed previously.</p>
</sec><sec id="s4k">
<title>Cell viability assays</title>
<p>Cell viability was assessed using a standard MTT assay as previously described <xref ref-type="bibr" rid="ppat.1000742-Tsutsumi1">[70]</xref>. A total of 5×10<sup>3</sup> RAW cells were incubated in individual wells in a 96-well plate for 24 h. Serial dilutions of L-NMMA were then added and after 24–48 h, cells were incubated in 1 mg/ml of MTT solution (Sigma-Aldrich) at 37°C for 3 h then 50% DMSO overnight and optical density at 570 nm determined by spectrophotometer (Thermo Labsystems). For assessing cell viability in an environment of oxidative stress, we transfected or infected RAW cells with pcDNA-miRNA (pcDNA control) or KSHV (or UV-KSHV control) in the presence of siRNA targeting xCT or control non-target siRNA. Thereafter, cells were incubated for 12 h with SNAP and cell viability determined using 0.4% trypan blue (MP Biomedicals, Solon, Ohio) to identify dead cells under light microscopy. Relative differences for cell viability between groups was determined as follows: relative cell viability = dead cells per 200 cells in experimental group/dead cells per 200 cells in vehicle control group.</p>
</sec><sec id="s4l">
<title>PCR</title>
<p>Total DNA was isolated using the QIAamp DNA Mini kit (QIAGEN). Briefly, cells were trypsinized for 5′ at 37°C and collected with 1 mL of ice-cold DMEM. Cells were pelleted at 2,000 rpm for 5′, washed, and resuspended in 200 µL of 1-phosphate-buffered saline (PBS), and total DNA was prepared according to the manufacturer's instructions. Total RNA was isolated using the RNeasy Mini kit (QIAGEN) as previously demonstrated <xref ref-type="bibr" rid="ppat.1000742-Parsons1">[41]</xref>. cDNA was synthesized from total RNA using SuperScript III First-Strand Synthesis SuperMix Kit (Invitrogen) according to the manufacturer's instructions. Coding sequences for genes of interest and β-actin (loading control) were amplified from 200 ng input cDNA and using iQ SYBR Green Supermix (Bio-rad). Custom primers sequences used for amplification experiments (Operon) were as follows: <italic>LANA sense <named-content content-type="gene" xlink:type="simple">5′ TCCCTCTACACTAAACCCAATA 3′</named-content>; LANA antisense <named-content content-type="gene" xlink:type="simple">5′ TTGCTAATCTCGTTGTCCC 3′</named-content>; BACH-1 sense <named-content content-type="gene" xlink:type="simple">5′ AGGACCTCACGGGCTCTA 3′</named-content>; BACH-1 antisense <named-content content-type="gene" xlink:type="simple">5′ ACCCAACCAGGGACACTC 3′</named-content>; xCT sense <named-content content-type="gene" xlink:type="simple">5′ GGTGGAACTGCTCGTAAT 3′</named-content>; xCT antisense <named-content content-type="gene" xlink:type="simple">5′ CAAAGATCGGGACTGCTA 3′</named-content>; β-actin sense <named-content content-type="gene" xlink:type="simple">5′ GGGAATGGGTCAGAAGGACT 3′</named-content>; β-actin antisense <named-content content-type="gene" xlink:type="simple">5′ TTTGATGTCACGCACGATTT 3′</named-content></italic>. Amplification experiments were carried out on an iCycler IQ Real-Time PCR Detection System, and cycle threshold (Ct) values tabulated in triplicate (DNA) or duplicate (cDNA) for each gene of interest for each experiment. “No template” (water) controls were also used to ensure minimal background contamination. Using mean Ct values tabulated for different experiments and Ct values for β-actin as loading controls, fold changes for experimental groups relative to assigned controls were calculated using automated iQ5 2.0 software (Bio-rad). Target amplification for semi-quantitative PCR (RT-PCR) was performed using a DNA thermal cycler (Gene Amp PCR System 9700, Applied Biosystems) under conditions of 94°C for 5′, 35 cycles of 94°C for 30 s, 54°C for 30 s, and 72°C for 60 s. Amplicons were subsequently identified by ethidium bromide-loaded agarose gel electrophoresis.</p>
</sec><sec id="s4m">
<title>Immunohistochemistry</title>
<p>Archived, paraffin-embedded KS skin lesions were collected from the Medical University of South Carolina (MUSC) Hollings Cancer Center Tumor Bank and the Maize Center for Dermatopathology (Charleston, S.C.). The diagnosis of KS and the histopathologic stage of each lesion were verified by an independent dermatopathologist. Histopathologic staging was determined using published criteria <xref ref-type="bibr" rid="ppat.1000742-Grayson1">[71]</xref> to characterize lesions as patches, plaques or nodules (with nodules representing the most advanced lesional stage). Tissue sections were deparaffinized and hydrated through xylene and graded alcohol series, rinsed for 5′ in distilled water, incubated for 10′ in 3% hydrogen peroxide, and following PBS wash, incubated for 30′ in a commercial antigen retrieval solution (Vector Laboratories, Burlingame, CA) at 100°C. Thereafter, all sections were incubated in 100% rabbit serum for 30′ to reduce non-specific staining then for 1 hour with either control preimmune rabbit sera or xCT antisera diluted 1∶400. In parallel, representative sections were incubated with 1∶1200 dilution of the anti-LANA rat monoclonal antibody (ABI). All sections were subsequently incubated for 30′ with a commercially available biotinylated secondary antibody and reagents according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA). Bound antibodies were recognized using a 3,3′- Diaminobenzidine (DAB) substrate and nuclei identified using either hematoxylin to contrast xCT expression, or Methyl Green to contrast LANA expression. xCT expression was determined for at least 8 independent tumors representing each of three histopathologic stages of KS (patches, plaques, and nodules). LANA expression was determined for patch and nodular lesions in this cohort.</p>
</sec><sec id="s4n">
<title>Statistical analysis</title>
<p>Significance for differences between experimental and control groups was determined using the two-tailed Student's t-test (Excel 8.0), and p values &lt;0.05 or &lt;0.01 were considered significant or highly significant, respectively.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="ppat.1000742.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.s001" xlink:type="simple"><label>Figure S1</label><caption>
<p>Upregulation of xCT does not increase the total number of infected HUVEC. (A) HUVEC were incubated with vehicle (DMSO), Msg or Sul for 12 h followed by purified KSHV at MOI∼0.5–1 for which a fraction (approximately 20%) of control HUVEC exhibited no LANA expression 16 h later by IFA. (B) HUVEC were transfected with either control vector or miRNA-expressing vectors along with an inhibitor of miR-K12-11 or either control non-target siRNA (n) or xCT-specific siRNA prior to their incubation with KSHV. Relative infection rates were determined for all groups as previously described. Error bars represent the S.E.M. for three independent experiments.</p>
<p>(0.07 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="ppat.1000742.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.s002" xlink:type="simple"><label>Figure S2</label><caption>
<p>KSHV miRNAs induce RNS release by macrophages independent of toll-like receptor pathway activation. (A) RAW cells were transiently transfected with either control or miRNA-expressing vectors for 24 h, then incubated with 10 mM 2-aminopurine (2-AP) or vehicle control for 3 h. (B) In parallel, RAW cells were transfected as in (A), then incubated with 100 µM of a control peptide or MyD88 inhibitor peptide for 24 h prior to nitrite quantification within culture supernatants. Error bars represent the S.E.M. for three independent experiments. * = p&lt;0.05.</p>
<p>(0.08 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="ppat.1000742.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.s003" xlink:type="simple"><label>Figure S3</label><caption>
<p>L-NMMA induces no discernable toxicity for RAW cells. RAW cells were incubated with the indicated concentrations of L-NMMA and cell viability determined after 48 h by standard MTT assay according to the manufacturer's instructions. Error bars represent the S.E.M. for three independent experiments.</p>
<p>(0.09 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="ppat.1000742.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.ppat.1000742.s004" xlink:type="simple"><label>Figure S4</label><caption>
<p>Advanced KS lesions contain more KSHV-infected cells relative to early-stage lesions. Representative early (I) and late (III) stage lesions were processed for immunohistochemistry as described in <xref ref-type="sec" rid="s4">Methods</xref> using secondary antibodies alone (control) or anti-LANA antibodies followed by secondary antibodies (LANA). LANA expression is indicated by dark brown, punctate intranuclear staining seen best at higher power (representative LANA<sup>+</sup> cells are identified with red arrows). Images are shown at original magnification ×20 or 50.</p>
<p>(1.60 MB TIF)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="ppat.1000742-Luppi1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Luppi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Barozzi</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Schulz</surname><given-names>TF</given-names></name>
<name name-style="western"><surname>Setti</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Staskus</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Bone marrow failure associated with human herpesvirus 8 infection after transplantation.</article-title>             <source>N Engl J Med</source>             <volume>343</volume>             <fpage>1378</fpage>             <lpage>1385</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Soulier1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Soulier</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Grollet</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Oksenhendler</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Cacoub</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Cazals-Hatem</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>1995</year>             <article-title>Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.</article-title>             <source>Blood</source>             <volume>86</volume>             <fpage>1276</fpage>             <lpage>1280</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Cesarman1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>PS</given-names></name>
<name name-style="western"><surname>Said</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Knowles</surname><given-names>DM</given-names></name>
</person-group>             <year>1995</year>             <article-title>Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.</article-title>             <source>N Engl J Med</source>             <volume>332</volume>             <fpage>1186</fpage>             <lpage>1191</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Chang1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Cesarman</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Pessin</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Culpepper</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>1994</year>             <article-title>Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.</article-title>             <source>Science</source>             <volume>266</volume>             <fpage>1865</fpage>             <lpage>1869</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Engels1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Engels</surname><given-names>EA</given-names></name>
<name name-style="western"><surname>Biggar</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Hall</surname><given-names>HI</given-names></name>
<name name-style="western"><surname>Cross</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Crutchfield</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Cancer risk in people infected with human immunodeficiency virus in the United States.</article-title>             <source>Int J Cancer</source>             <volume>123</volume>             <fpage>187</fpage>             <lpage>194</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Bonnet1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bonnet</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Lewden</surname><given-names>C</given-names></name>
<name name-style="western"><surname>May</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Heripret</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Jougla</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.</article-title>             <source>Cancer</source>             <volume>101</volume>             <fpage>317</fpage>             <lpage>324</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lebbe1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lebbe</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Legendre</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Frances</surname><given-names>C</given-names></name>
</person-group>             <year>2008</year>             <article-title>Kaposi sarcoma in transplantation.</article-title>             <source>Transplant Rev (Orlando)</source>             <volume>22</volume>             <fpage>252</fpage>             <lpage>261</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Shepherd1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Shepherd</surname><given-names>FA</given-names></name>
<name name-style="western"><surname>Maher</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Cardella</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Cole</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Greig</surname><given-names>P</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Treatment of Kaposi's sarcoma after solid organ transplantation.</article-title>             <source>J Clin Oncol</source>             <volume>15</volume>             <fpage>2371</fpage>             <lpage>2377</lpage>          </element-citation></ref>
<ref id="ppat.1000742-CookMozaffari1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cook-Mozaffari</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Newton</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Beral</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Burkitt</surname><given-names>DP</given-names></name>
</person-group>             <year>1998</year>             <article-title>The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic.</article-title>             <source>Br J Cancer</source>             <volume>78</volume>             <fpage>1521</fpage>             <lpage>1528</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Vanni1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Vanni</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Sprinz</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Machado</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Santana Rde</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Fonseca</surname><given-names>BA</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives.</article-title>             <source>Cancer Treat Rev</source>             <volume>32</volume>             <fpage>445</fpage>             <lpage>455</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Maurer1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Maurer</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Ponte</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Leslie</surname><given-names>K</given-names></name>
</person-group>             <year>2007</year>             <article-title>HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load.</article-title>             <source>N Engl J Med</source>             <volume>357</volume>             <fpage>1352</fpage>             <lpage>1353</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Krown1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Krown</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>
<name name-style="western"><surname>Dittmer</surname><given-names>DP</given-names></name>
</person-group>             <year>2008</year>             <article-title>More on HIV-associated Kaposi's sarcoma.</article-title>             <source>N Engl J Med</source>             <volume>358</volume>             <fpage>535</fpage>             <lpage>536; author reply 536</lpage>          </element-citation></ref>
<ref id="ppat.1000742-VonRoenn1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Von Roenn</surname><given-names>JH</given-names></name>
</person-group>             <year>2003</year>             <article-title>Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma.</article-title>             <source>Hematol Oncol Clin North Am</source>             <volume>17</volume>             <fpage>747</fpage>             <lpage>762</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Schulz1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Schulz</surname><given-names>TF</given-names></name>
</person-group>             <year>2006</year>             <article-title>The pleiotropic effects of Kaposi's sarcoma herpesvirus.</article-title>             <source>J Pathol</source>             <volume>208</volume>             <fpage>187</fpage>             <lpage>198</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Campbell1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Campbell</surname><given-names>TB</given-names></name>
<name name-style="western"><surname>Borok</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gwanzura</surname><given-names>L</given-names></name>
<name name-style="western"><surname>MaWhinney</surname><given-names>S</given-names></name>
<name name-style="western"><surname>White</surname><given-names>IE</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage.</article-title>             <source>AIDS</source>             <volume>14</volume>             <fpage>2109</fpage>             <lpage>2116</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Quinlivan1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Quinlivan</surname><given-names>EB</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Stewart</surname><given-names>PW</given-names></name>
<name name-style="western"><surname>Komoltri</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Davis</surname><given-names>MG</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not.</article-title>             <source>J Infect Dis</source>             <volume>185</volume>             <fpage>1736</fpage>             <lpage>1744</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Dupin1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dupin</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Fisher</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kellam</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Ariad</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tulliez</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>96</volume>             <fpage>4546</fpage>             <lpage>4551</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Kedes1"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kedes</surname><given-names>DH</given-names></name>
<name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name>
</person-group>             <year>1997</year>             <article-title>Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.</article-title>             <source>J Clin Invest</source>             <volume>99</volume>             <fpage>2082</fpage>             <lpage>2086</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Martin1"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Martin</surname><given-names>DF</given-names></name>
<name name-style="western"><surname>Kuppermann</surname><given-names>BD</given-names></name>
<name name-style="western"><surname>Wolitz</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Palestine</surname><given-names>AG</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.</article-title>             <source>N Engl J Med</source>             <volume>340</volume>             <fpage>1063</fpage>             <lpage>1070</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lambert1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lambert</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gannage</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Karras</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Abel</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Legendre</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma.</article-title>             <source>Blood</source>             <volume>108</volume>             <fpage>3871</fpage>             <lpage>3880</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Bihl1"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bihl</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Mosam</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Henry</surname><given-names>LN</given-names></name>
<name name-style="western"><surname>Chisholm</surname><given-names>JV</given-names><suffix>3rd</suffix></name>
<name name-style="western"><surname>Dollard</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.</article-title>             <source>AIDS</source>             <volume>21</volume>             <fpage>1245</fpage>             <lpage>1252</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Grundhoff1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Grundhoff</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name>
</person-group>             <year>2004</year>             <article-title>Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.</article-title>             <source>J Clin Invest</source>             <volume>113</volume>             <fpage>124</fpage>             <lpage>136</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lebbe2"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lebbe</surname><given-names>C</given-names></name>
<name name-style="western"><surname>de Cremoux</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Millot</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Podgorniak</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Verola</surname><given-names>O</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Characterization of in vitro culture of HIV-negative Kaposi's sarcoma-derived cells. In vitro responses to alfa interferon.</article-title>             <source>Arch Dermatol Res</source>             <volume>289</volume>             <fpage>421</fpage>             <lpage>428</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Tsuchiya1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tsuchiya</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kobayashi</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Goto</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Okumura</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Nakae</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>1982</year>             <article-title>Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.</article-title>             <source>Cancer Res</source>             <volume>42</volume>             <fpage>1530</fpage>             <lpage>1536</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lo1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lo</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>YZ</given-names></name>
<name name-style="western"><surname>Gout</surname><given-names>PW</given-names></name>
</person-group>             <year>2008</year>             <article-title>The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.</article-title>             <source>J Cell Physiol</source>             <volume>215</volume>             <fpage>593</fpage>             <lpage>602</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Kaleeba1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kaleeba</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>EA</given-names></name>
</person-group>             <year>2006</year>             <article-title>Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT.</article-title>             <source>Science</source>             <volume>311</volume>             <fpage>1921</fpage>             <lpage>1924</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Veettil1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Veettil</surname><given-names>MV</given-names></name>
<name name-style="western"><surname>Sadagopan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sharma-Walia</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>FZ</given-names></name>
<name name-style="western"><surname>Raghu</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Kaposi's sarcoma-associated herpesvirus forms a multimolecular complex of integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during infection of human dermal microvascular endothelial cells, and CD98-xCT is essential for the post entry stage of infection.</article-title>             <source>J Virol</source>             <volume>82</volume>             <fpage>12126</fpage>             <lpage>12144</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Sirianni1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sirianni</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Vincenzi</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Topino</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Scala</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Uccini</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Angeloni</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Faggioni</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Cerimele</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Cottoni</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Aiuti</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name>
</person-group>             <article-title>Gamma-interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood monocytes and lesional macrophages.</article-title>             <source>Blood</source>             <volume>1998; 91(3)</volume>             <fpage>968</fpage>             <lpage>76</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Rappocciolo1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rappocciolo</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Jenkins</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Hensler</surname><given-names>HR</given-names></name>
<name name-style="western"><surname>Piazza</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Jais</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages.</article-title>             <source>J Immunol</source>             <volume>176</volume>             <fpage>1741</fpage>             <lpage>1749</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Ganem1"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Ziegelbauer</surname><given-names>J</given-names></name>
</person-group>             <year>2008</year>             <article-title>MicroRNAs of Kaposi's sarcoma-associated herpes virus.</article-title>             <source>Semin Cancer Biol</source>             <volume>18</volume>             <fpage>437</fpage>             <lpage>440</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Cai1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cai</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Gonzalez</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Damania</surname><given-names>B</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>102</volume>             <fpage>5570</fpage>             <lpage>5575</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Samols1"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Samols</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Skalsky</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Renne</surname><given-names>R</given-names></name>
</person-group>             <year>2005</year>             <article-title>Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus.</article-title>             <source>J Virol</source>             <volume>79</volume>             <fpage>9301</fpage>             <lpage>9305</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Pfeffer1"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pfeffer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sewer</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Lagos-Quintana</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sheridan</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Sander</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Identification of microRNAs of the herpesvirus family.</article-title>             <source>Nat Methods</source>             <volume>2</volume>             <fpage>269</fpage>             <lpage>276</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Sasaki1"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sasaki</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Sato</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Kuriyama-Matsumura</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Sato</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Maebara</surname><given-names>K</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression.</article-title>             <source>J Biol Chem</source>             <volume>277</volume>             <fpage>44765</fpage>             <lpage>44771</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Ishii1"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ishii</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Itoh</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Takahashi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sato</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Yanagawa</surname><given-names>T</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages.</article-title>             <source>J Biol Chem</source>             <volume>275</volume>             <fpage>16023</fpage>             <lpage>16029</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Skalsky1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Skalsky</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Samols</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Plaisance</surname><given-names>KB</given-names></name>
<name name-style="western"><surname>Boss</surname><given-names>IW</given-names></name>
<name name-style="western"><surname>Riva</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>12836</fpage>             <lpage>12845</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Dhakshinamoorthy1"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dhakshinamoorthy</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Jain</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>Bloom</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Jaiswal</surname><given-names>AK</given-names></name>
</person-group>             <year>2005</year>             <article-title>Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants.</article-title>             <source>J Biol Chem</source>             <volume>280</volume>             <fpage>16891</fpage>             <lpage>16900</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Dhakshinamoorthy2"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dhakshinamoorthy</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Jaiswal</surname><given-names>AK</given-names></name>
</person-group>             <year>2002</year>             <article-title>c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction.</article-title>             <source>Oncogene</source>             <volume>21</volume>             <fpage>5301</fpage>             <lpage>5312</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Hong1"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hong</surname><given-names>YK</given-names></name>
<name name-style="western"><surname>Foreman</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Hirakawa</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Curry</surname><given-names>CL</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus.</article-title>             <source>Nat Genet</source>             <volume>36</volume>             <fpage>683</fpage>             <lpage>685</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Rodriguez1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Vigorito</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Clare</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Warren</surname><given-names>MV</given-names></name>
<name name-style="western"><surname>Couttet</surname><given-names>P</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Requirement of bic/microRNA-155 for normal immune function.</article-title>             <source>Science</source>             <volume>316</volume>             <fpage>608</fpage>             <lpage>611</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Parsons1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Parsons</surname><given-names>CH</given-names></name>
<name name-style="western"><surname>Adang</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Overdevest</surname><given-names>J</given-names></name>
<name name-style="western"><surname>O'Connor</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>JR,</given-names><suffix>Jr.</suffix></name>
<etal/></person-group>             <year>2006</year>             <article-title>KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice.</article-title>             <source>J Clin Invest</source>             <volume>116</volume>             <fpage>1963</fpage>             <lpage>1973</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Gout1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gout</surname><given-names>PW</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>YJ</given-names></name>
<name name-style="western"><surname>Buckley</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Bruchovsky</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Buckley</surname><given-names>AR</given-names></name>
</person-group>             <year>1997</year>             <article-title>Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells.</article-title>             <source>Leukemia</source>             <volume>11</volume>             <fpage>1329</fpage>             <lpage>1337</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Gout2"><label>43</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gout</surname><given-names>PW</given-names></name>
<name name-style="western"><surname>Simms</surname><given-names>CR</given-names></name>
<name name-style="western"><surname>Robertson</surname><given-names>MC</given-names></name>
</person-group>             <year>2003</year>             <article-title>In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine.</article-title>             <source>Anticancer Drugs</source>             <volume>14</volume>             <fpage>21</fpage>             <lpage>29</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Samols2"><label>44</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Samols</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Skalsky</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Maldonado</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Riva</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Lopez</surname><given-names>MC</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Identification of cellular genes targeted by KSHV-encoded microRNAs.</article-title>             <source>PLoS Pathog</source>             <volume>3</volume>             <fpage>e65</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.0030065" xlink:type="simple">10.1371/journal.ppat.0030065</ext-link></comment>          </element-citation></ref>
<ref id="ppat.1000742-Guidarelli1"><label>45</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Guidarelli</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sciorati</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Clementi</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Cantoni</surname><given-names>O</given-names></name>
</person-group>             <year>2006</year>             <article-title>Peroxynitrite mobilizes calcium ions from ryanodine-sensitive stores, a process associated with the mitochondrial accumulation of the cation and the enforced formation of species mediating cleavage of genomic DNA.</article-title>             <source>Free Radic Biol Med</source>             <volume>41</volume>             <fpage>154</fpage>             <lpage>164</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Frey1"><label>46</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Frey</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Ushio-Fukai</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Malik</surname><given-names>A</given-names></name>
</person-group>             <year>2009</year>             <article-title>NADPH Oxidase-Dependent Signaling in Endothelial Cells: Role in Physiology and Pathophysiology.</article-title>             <source>Antioxid Redox Signal</source>             <volume>11</volume>             <fpage>791</fpage>             <lpage>810</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lambeth1"><label>47</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lambeth</surname><given-names>JD</given-names></name>
</person-group>             <year>2004</year>             <article-title>NOX enzymes and the biology of reactive oxygen.</article-title>             <source>Nat Rev Immunol</source>             <volume>4</volume>             <fpage>181</fpage>             <lpage>189</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Asehnoune1"><label>48</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Asehnoune</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Strassheim</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Mitra</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name>
<name name-style="western"><surname>Abraham</surname><given-names>E</given-names></name>
</person-group>             <year>2004</year>             <article-title>Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B.</article-title>             <source>J Immunol</source>             <volume>172</volume>             <fpage>2522</fpage>             <lpage>2529</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Lee1"><label>49</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Namkoong</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>CK</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>YC</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine.</article-title>             <source>J Biol Chem</source>             <volume>280</volume>             <fpage>5781</fpage>             <lpage>5788</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Mallery1"><label>50</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mallery</surname><given-names>SR</given-names></name>
<name name-style="western"><surname>Pei</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Landwehr</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Clark</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Bradburn</surname><given-names>JE</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma.</article-title>             <source>Carcinogenesis</source>             <volume>25</volume>             <fpage>597</fpage>             <lpage>603</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Alexander1"><label>51</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Alexander</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Reynolds</surname><given-names>HR</given-names></name>
<name name-style="western"><surname>Stebbins</surname><given-names>AL</given-names></name>
<name name-style="western"><surname>Dzavik</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Harrington</surname><given-names>RA</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.</article-title>             <source>JAMA</source>             <volume>297</volume>             <fpage>1657</fpage>             <lpage>1666</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Pak1"><label>52</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pak</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Pyakural</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Kokhaei</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Kaaya</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Pourfathollah</surname><given-names>AA</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry.</article-title>             <source>J Cutan Pathol</source>             <volume>32</volume>             <fpage>21</fpage>             <lpage>27</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Pyakurel1"><label>53</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pyakurel</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Massambu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Castanos-Velez</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Ericsson</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kaaya</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>36</volume>             <fpage>678</fpage>             <lpage>683</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Gill1"><label>54</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gill</surname><given-names>PS</given-names></name>
<name name-style="western"><surname>Tsai</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Rao</surname><given-names>AP</given-names></name>
<name name-style="western"><surname>Spruck</surname><given-names>CH</given-names><suffix>3rd</suffix></name>
<name name-style="western"><surname>Zheng</surname><given-names>T</given-names></name>
<etal/></person-group>             <year>1998</year>             <article-title>Evidence for multiclonality in multicentric Kaposi's sarcoma.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>95</volume>             <fpage>8257</fpage>             <lpage>8261</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Staskus1"><label>55</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Staskus</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Gebhard</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Herndier</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.</article-title>             <source>J Virol</source>             <volume>71</volume>             <fpage>715</fpage>             <lpage>719</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Boulanger1"><label>56</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Boulanger</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Duprez</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Delabesse</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Gabarre</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Macintyre</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells.</article-title>             <source>Int J Cancer</source>             <volume>115</volume>             <fpage>511</fpage>             <lpage>518</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Adang1"><label>57</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Adang</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Tomescu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Law</surname><given-names>WK</given-names></name>
<name name-style="western"><surname>Kedes</surname><given-names>DH</given-names></name>
</person-group>             <year>2007</year>             <article-title>Intracellular Kaposi's sarcoma-associated herpesvirus load determines early loss of immune synapse components.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>5079</fpage>             <lpage>5090</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Babcock1"><label>58</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Babcock</surname><given-names>GJ</given-names></name>
<name name-style="western"><surname>Decker</surname><given-names>LL</given-names></name>
<name name-style="western"><surname>Freeman</surname><given-names>RB</given-names></name>
<name name-style="western"><surname>Thorley-Lawson</surname><given-names>DA</given-names></name>
</person-group>             <year>1999</year>             <article-title>Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.</article-title>             <source>J Exp Med</source>             <volume>190</volume>             <fpage>567</fpage>             <lpage>576</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Adang2"><label>59</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Adang</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Parsons</surname><given-names>CH</given-names></name>
<name name-style="western"><surname>Kedes</surname><given-names>DH</given-names></name>
</person-group>             <year>2006</year>             <article-title>Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection.</article-title>             <source>J Virol</source>             <volume>80</volume>             <fpage>10073</fpage>             <lpage>10082</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Zhu1"><label>60</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Marshall</surname><given-names>ZM</given-names></name>
<name name-style="western"><surname>Whorton</surname><given-names>AR</given-names></name>
</person-group>             <year>2008</year>             <article-title>A cystine-cysteine shuttle mediated by xCT facilitates cellular responses to S-nitrosoalbumin.</article-title>             <source>Am J Physiol Cell Physiol</source>             <volume>294</volume>             <fpage>C1012</fpage>             <lpage>1020</lpage>          </element-citation></ref>
<ref id="ppat.1000742-McAllister1"><label>61</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>McAllister</surname><given-names>SC</given-names></name>
<name name-style="western"><surname>Hansen</surname><given-names>SG</given-names></name>
<name name-style="western"><surname>Ruhl</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Raggo</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>DeFilippis</surname><given-names>VR</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells.</article-title>             <source>Blood</source>             <volume>103</volume>             <fpage>3465</fpage>             <lpage>3473</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Weninger1"><label>62</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Weninger</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Rendl</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pammer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Mildner</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Tschugguel</surname><given-names>W</given-names></name>
<etal/></person-group>             <year>1998</year>             <article-title>Nitric oxide synthases in Kaposi's sarcoma are expressed predominantly by vessels and tissue macrophages.</article-title>             <source>Lab Invest</source>             <volume>78</volume>             <fpage>949</fpage>             <lpage>955</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Pyo1"><label>63</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pyo</surname><given-names>CW</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name>
<name name-style="western"><surname>Choi</surname><given-names>SY</given-names></name>
</person-group>             <year>2008</year>             <article-title>Oxidative stress induces PKR-dependent apoptosis via IFN-gamma activation signaling in Jurkat T cells.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>377</volume>             <fpage>1001</fpage>             <lpage>1006</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Yanagisawa1"><label>64</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yanagisawa</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Shimada</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Miyazaki</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Kume</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kitamura</surname><given-names>Y</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages.</article-title>             <source>Lipids Health Dis</source>             <volume>7</volume>             <fpage>48</fpage>          </element-citation></ref>
<ref id="ppat.1000742-Kim1"><label>65</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>TB</given-names></name>
<name name-style="western"><surname>Moon</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>TJ</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo.</article-title>             <source>Exp Mol Med</source>             <volume>40</volume>             <fpage>461</fpage>             <lpage>476</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Ma1"><label>66</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Cavallin</surname><given-names>LE</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Duran</surname><given-names>EM</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>106</volume>             <fpage>8683</fpage>             <lpage>8688</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Thurau1"><label>67</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Thurau</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Marquardt</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Gonin-Laurent</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Weinlander</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Naschberger</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.</article-title>             <source>J Virol</source>             <volume>83</volume>             <fpage>598</fpage>             <lpage>611</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Yu1"><label>68</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yu</surname><given-names>JY</given-names></name>
<name name-style="western"><surname>Chung</surname><given-names>KH</given-names></name>
<name name-style="western"><surname>Deo</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Turner</surname><given-names>DL</given-names></name>
</person-group>             <year>2008</year>             <article-title>MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation.</article-title>             <source>Exp Cell Res</source>             <volume>314</volume>             <fpage>2618</fpage>             <lpage>2633</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Tomescu1"><label>69</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tomescu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Law</surname><given-names>WK</given-names></name>
<name name-style="western"><surname>Kedes</surname><given-names>DH</given-names></name>
</person-group>             <year>2003</year>             <article-title>Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>9669</fpage>             <lpage>9684</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Tsutsumi1"><label>70</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tsutsumi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Scroggins</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Koga</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Trepel</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.</article-title>             <source>Oncogene</source>             <volume>27</volume>             <fpage>2478</fpage>             <lpage>2487</lpage>          </element-citation></ref>
<ref id="ppat.1000742-Grayson1"><label>71</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Grayson</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Pantanowitz</surname><given-names>L</given-names></name>
</person-group>             <year>2008</year>             <article-title>Histological variants of cutaneous Kaposi sarcoma.</article-title>             <source>Diagn Pathol</source>             <volume>3</volume>             <fpage>31</fpage>          </element-citation></ref>
</ref-list>

</back>
</article>